See the DrugPatentWatch profile for orencia
Is Orencia Approved for Juvenile Idiopathic Arthritis (JIA)?
Yes, Orencia (abatacept) is FDA-approved for treating polyarticular juvenile idiopathic arthritis (pJIA) in children aged 2 and older.[1] It reduces joint inflammation and damage by blocking T-cell activation, often used when methotrexate alone fails.
How Is Orencia Given for JIA?
Orencia is administered weekly via subcutaneous injection or monthly IV infusion in pediatric patients. Dosing is weight-based: 10 mg/kg IV max 1,000 mg, or 125 mg subcutaneous for those under 75 kg.[1][2] Treatment typically starts after a trial of DMARDs like methotrexate.
What JIA Subtypes Does It Cover?
Primarily polyarticular JIA (affecting 5+ joints), including rheumatoid factor-positive and negative cases. It's not approved for systemic JIA or other subtypes like oligoarticular without polyarticular extension.[1]
How Effective Is It Compared to Other JIA Treatments?
In trials, 72% of children on Orencia plus methotrexate achieved ACR Pediatric 30 response (30% symptom improvement) at 4 months, versus 37% on methotrexate alone.[2] It outperforms placebo but is often combined with methotrexate for best results. Long-term data show sustained remission in about 50% over 5 years.[3]
What Are Common Side Effects in Kids with JIA?
Upper respiratory infections (37%), headaches (13%), nausea (11%), and infusion reactions occur most often. Serious risks include infections (e.g., pneumonia), malignancies (rare, 0.4%), and autoimmune issues like new psoriasis. Live vaccines are contraindicated during treatment.[1][2]
Who Makes Orencia and What's the Cost?
Bristol Myers Squibb manufactures Orencia. List price for a 4-week subcutaneous starter kit is around $5,500-$6,000 USD, varying by dose and insurance. Patient assistance programs cover many pediatric cases.[4]
When Do Orencia Patents Expire for JIA Use?
Key U.S. patents on abatacept expire in 2032-2034, with formulation patents challenged by generics like those from Fresenius Kabi. No biosimilars approved yet for subcutaneous form.[5] DrugPatentWatch.com
[1]: FDA Label for Orencia (2023) - https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125057s292lbl.pdf
[2]: Ruperto et al., Lancet (2008) - https://pubmed.ncbi.nlm.nih.gov/18424226/
[3]: Lovell et al., Arthritis Rheum (2013) - https://pubmed.ncbi.nlm.nih.gov/23400504/
[4]: Bristol Myers Squibb Pricing (2024) - https://www.orencia.com
[5]: DrugPatentWatch.com - https://www.drugpatentwatch.com/p/tradename/ORENCIA